Effect of Rosuvastatin on Fasting and Postprandial Lipid Profile in Hypertriglyceridemia Patients

Abdulkadir ÇAKMAK

doi:https://doi.org/10.22399/ijcesen.827419

Makale detayları

Effect of Rosuvastatin on Fasting and Postprandial Lipid Profile in Hypertriglyceridemia Patients

Yazarlar:

Abdulkadir ÇAKMAK

Yayıncı:

İskender AKKURT

Ana Başlıklar:

Hastalıklar

Dergi:

International Journal of Computational and Experimental Science and Engineering 2021 Vol.7 Issue 3, pp.146-155

Belge Tipi:

Makale

Yayın Tarihi:

11/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000476983

Sıklık:

Üç Yıllık

eISSN:

2149-9144

DOI:

https://doi.org/10.22399/ijcesen.827419

Özet:

 

Abstract: 

Background: Coronary heart disease (CHD) is a main cause of mortality due to cardiovascular diseases. Hypertriglyceridemia (HTG) is a multifactorial condition implicated in the pathogenesis of CHD. Serum triglyceride (TG) levels were routinely obtained under fasting conditions; however, recent evidences implicate that postprandial triglyceride levels may be more important for CHD risk. 
Aim: Aim of this study was to investigate the effect of rosuvastatin on fasting and postprandial TG levels in the patients with borderline-high TG levels.
Methods: 51 patients (18-75 years old; 26 female) with LDL-c between 100 and 160 mg/dL and triglyceride levels between 150 and 300 mg/dL were included in this study. Basal fasting and postprandial lipid profile and hsCRP levels of the patients were obtained and patients were requested to take 10 mg/day rosuvastatin for one month. At the end of one month, the measurements were repeated.
Results: Rosuvastatin significantly decreased both fasting and postprandial TG levels compared to basal levels (p<0.001). The decrease in the postprandial TG levels after rosuvastatin treatment were significantly higher than the decrease in fasting TG levels (p<0.001). No differences between genders were observed with regards to decrease in the fasting and postprandial TG levels. In patients with metabolic syndrome, rosuvastatin treatment decreased fasting and postprandial TG levels after one month, however, the change was not different from the patients without metabolic syndrome.
Conclusion: In conclusion, the decrease in postprandial TG levels after rosuvastatin treatment that was shown may be clinically important in prevention of CHD in HTG patients.

Makale detayları

Effect of Rosuvastatin on Fasting and Postprandial Lipid Profile in Hypertriglyceridemia Patients

Yazarlar: Abdulkadir ÇAKMAK

Yayıncı: İskender AKKURT

Ana Başlıklar: Hastalıklar

Dergi: International Journal of Computational and Experimental Science and Engineering 2021 Vol.7 Issue 3, pp.146-155

Belge Tipi: Makale

Yayın Tarihi: 11/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000476983

Sıklık: Üç Yıllık

eISSN: 2149-9144

DOI: https://doi.org/10.22399/ijcesen.827419

Sayı

Yazarlar:

Abdulkadir ÇAKMAK

Yayıncı:

İskender AKKURT

Ana Başlıklar:

Hastalıklar

Dergi:

International Journal of Computational and Experimental Science and Engineering 2021 Vol.7 Issue 3, pp.146-155

Belge Tipi:

Makale

Yayın Tarihi:

11/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000476983

Sıklık:

Üç Yıllık

eISSN:

2149-9144

DOI:

https://doi.org/10.22399/ijcesen.827419